311 related articles for article (PubMed ID: 16688783)
1. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.
Davis AM; Ellersieck MR; Grimm KM; Rosenfeld CS
Mol Reprod Dev; 2006 Aug; 73(8):1034-44. PubMed ID: 16688783
[TBL] [Abstract][Full Text] [Related]
2. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM
Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242
[TBL] [Abstract][Full Text] [Related]
3. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.
Bläuer M; Heinonen PK; Rovio P; Ylikomi T
Eur J Pharmacol; 2008 Sep; 592(1-3):13-8. PubMed ID: 18638473
[TBL] [Abstract][Full Text] [Related]
4. Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
Carthew P; Edwards RE; Nolan BM
Toxicol Appl Pharmacol; 1999 Jul; 158(1):24-32. PubMed ID: 10387929
[TBL] [Abstract][Full Text] [Related]
5. Effects of raloxifene hydrochloride on endometrial cancer cells in vitro.
Hibner M; Magrina JF; Lefler SR; Cornella JL; Pizarro AR; Loftus JC
Gynecol Oncol; 2004 Jun; 93(3):642-6. PubMed ID: 15196858
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
[TBL] [Abstract][Full Text] [Related]
7. Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.
Pole JC; Gold LI; Orton T; Huby R; Carmichael PL
Toxicology; 2005 Jan; 206(1):91-109. PubMed ID: 15590111
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile.
Gallo D; Zannoni GF; Apollonio P; Martinelli E; Ferlini C; Passetti G; Riva A; Morazzoni P; Bombardelli E; Scambia G
Menopause; 2005; 12(5):589-600. PubMed ID: 16145313
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim IY; Kim BC; Seong DH; Lee DK; Seo JM; Hong YJ; Kim HT; Morton RA; Kim SJ
Cancer Res; 2002 Sep; 62(18):5365-9. PubMed ID: 12235008
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of estrogenic effects by dihydrotestosterone in the pig uterus is associated with downregulation of the estrogen receptors.
Cárdenas H; Pope WF
Biol Reprod; 2004 Feb; 70(2):297-302. PubMed ID: 14522825
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of estrogen receptor expression in the uterus of ovariectomized B6C3F1 mice and Ishikawa cells treated with bromoethane.
Aoyama H; Couse JF; Hewitt SC; Haseman JK; He H; Zheng X; Majstoravich S; Korach KS; Dixon D
Toxicol Appl Pharmacol; 2005 Dec; 209(3):226-35. PubMed ID: 15922381
[TBL] [Abstract][Full Text] [Related]
12. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland.
Crabtree JS; Peano BJ; Zhang X; Komm BS; Winneker RC; Harris HA
Mol Cell Endocrinol; 2008 Jun; 287(1-2):40-6. PubMed ID: 18367319
[TBL] [Abstract][Full Text] [Related]
13. Growth response of colon cancer cell lines to selective estrogen receptor modulators.
Picariello L; Fiorelli G; Martineti V; Tognarini I; Pampaloni B; Tonelli F; Brandi ML
Anticancer Res; 2003; 23(3B):2419-24. PubMed ID: 12894523
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.
Sonpavde G; Okuno N; Weiss H; Yu J; Shen SS; Younes M; Jian W; Lerner SP; Smith CL
Urology; 2007 Jun; 69(6):1221-6. PubMed ID: 17572228
[TBL] [Abstract][Full Text] [Related]
15. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
16. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.
Liu J; Matsuo H; Xu Q; Chen W; Wang J; Maruo T
Hum Reprod; 2007 May; 22(5):1253-9. PubMed ID: 17220163
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells.
Morishima S; Shibata MA; Ohmichi M; Otsuki Y
Med Mol Morphol; 2008 Sep; 41(3):132-8. PubMed ID: 18807138
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of estradiol, raloxifene, and genistein on the uterus of ovariectomized mice.
García-Pérez MA; Noguera R; del Val R; Noguera I; Hermenegildo C; Cano A
Fertil Steril; 2006 Oct; 86(4):1003-5. PubMed ID: 16963036
[TBL] [Abstract][Full Text] [Related]
19. Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines.
Sasaki H; Hayakawa J; Terai Y; Kanemura M; Tanabe-Kimura A; Kamegai H; Seino-Noda H; Ezoe S; Matsumura I; Kanakura Y; Sakata M; Tasaka K; Ohmichi M
Oncogene; 2008 Apr; 27(19):2737-45. PubMed ID: 18193094
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus.
Davis AM; Mao J; Naz B; Kohl JA; Rosenfeld CS
J Mol Endocrinol; 2008 Oct; 41(4):205-17. PubMed ID: 18632874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
